Regulatory affairs fin
-
Upload
marina-hurtado-mira -
Category
Business
-
view
676 -
download
4
description
Transcript of Regulatory affairs fin
![Page 1: Regulatory affairs fin](https://reader033.fdocuments.net/reader033/viewer/2022050815/5456ad74af79592b438b6562/html5/thumbnails/1.jpg)
Marina Hurtado MiraMarina Hurtado MiraRegulatory Affairs AssociateRegulatory Affairs Associate
![Page 2: Regulatory affairs fin](https://reader033.fdocuments.net/reader033/viewer/2022050815/5456ad74af79592b438b6562/html5/thumbnails/2.jpg)
•Regulatory Affairs Department
•Role Regulatory Affairs
•Marketing Approvals Ways
Centralised Procedure
Mutual Recognition Procedure
National Procedure
•Post-approval
•European Medicines Agency’s Role
•Evaluation by EMA
![Page 3: Regulatory affairs fin](https://reader033.fdocuments.net/reader033/viewer/2022050815/5456ad74af79592b438b6562/html5/thumbnails/3.jpg)
REGULATORY AFFAIRS DEPT
![Page 4: Regulatory affairs fin](https://reader033.fdocuments.net/reader033/viewer/2022050815/5456ad74af79592b438b6562/html5/thumbnails/4.jpg)
MAA – Marketing Authorization Application
Prepare and submit the documents to regulatory
agencies
To give strategic and technical advice to the
departments; production, QC dept, QA, price and r;
marketing…
ROLE OF RA
![Page 5: Regulatory affairs fin](https://reader033.fdocuments.net/reader033/viewer/2022050815/5456ad74af79592b438b6562/html5/thumbnails/5.jpg)
Marketing Approval Ways
Centralised Procedure (CP)Mutual Recognition (MRP) /
Decentralised Procedure (DCP)
National Procedure (NP)
Better resources utilisation
Harmonised scientific opinions
Harmonised information for doctors
![Page 6: Regulatory affairs fin](https://reader033.fdocuments.net/reader033/viewer/2022050815/5456ad74af79592b438b6562/html5/thumbnails/6.jpg)
Centralised Procedure
MA
SmPC
PL
Labelling
Invented name
HIV/AIDS, cancer, diabetes,
neurodegenerative diseases, auto-
immune and viral diseases;
medicines derived from:
-biotechnology processes
-advanced-therapy medicines, orphan
drugs
HIV/AIDS, cancer, diabetes,
neurodegenerative diseases, auto-
immune and viral diseases;
medicines derived from:
-biotechnology processes
-advanced-therapy medicines, orphan
drugs
OPTION APPLICATION
Mandatory
![Page 7: Regulatory affairs fin](https://reader033.fdocuments.net/reader033/viewer/2022050815/5456ad74af79592b438b6562/html5/thumbnails/7.jpg)
Mutual Recognition Procedure / MRP
National licensed approved 1 member State RMS
RMS: Reference Member StateCMS: Concerned Member State
During recognization ask others
countries to
recognise the positive
opinion
![Page 8: Regulatory affairs fin](https://reader033.fdocuments.net/reader033/viewer/2022050815/5456ad74af79592b438b6562/html5/thumbnails/8.jpg)
NATIONAL PROCEDURE / NP
Evaluation by AEMPS
Authorisation by AEMPS
New National Application / NNA
Dossier to AEMPS
Validation
Evaluation
Authorisation
RAEFAR Nees / eCTD
![Page 9: Regulatory affairs fin](https://reader033.fdocuments.net/reader033/viewer/2022050815/5456ad74af79592b438b6562/html5/thumbnails/9.jpg)
POST-APPROVALDevelopment of strategies
-changes to manufacturing process
-changes to product characteristics
-additional indications
Responses to the Agencies
Organisation for future issues
Discussion of variation strategies and timing
![Page 10: Regulatory affairs fin](https://reader033.fdocuments.net/reader033/viewer/2022050815/5456ad74af79592b438b6562/html5/thumbnails/10.jpg)
EMA
AGENCY’S
ROLEEvaluation of applications – efficient and transparent
Provision of Advice (optional)
Control of safety
Evaluation for orphan designation
Evaluation for Pediatrics investigations - PIP
Provide good and independient information
![Page 11: Regulatory affairs fin](https://reader033.fdocuments.net/reader033/viewer/2022050815/5456ad74af79592b438b6562/html5/thumbnails/11.jpg)
96 applications
EU is a Single for pharmaceuticals
The main scientific principle used in the evaluation of medicines is the benefit/ risk balance, based mainly on quality, efficacy and safety
Evaluation by the European Agency
![Page 12: Regulatory affairs fin](https://reader033.fdocuments.net/reader033/viewer/2022050815/5456ad74af79592b438b6562/html5/thumbnails/12.jpg)
Evaluation by the European Agency
Adopts an opinion
SCIENTIFIC COMMITTEES
CHMP
CVMP
COMP
HMPC
CP – PIP
ATC
Chairman
Vice Chairman
5 experts (area) co-opted members
1 per month
27 MS
![Page 13: Regulatory affairs fin](https://reader033.fdocuments.net/reader033/viewer/2022050815/5456ad74af79592b438b6562/html5/thumbnails/13.jpg)
Evaluation by the European Agency
CHMP Adopts an opinion “Day 210”
- Marketed or not
This opinion “ European Commission “ 270 days
- The ultimate authority for granting marketing
authorisations in the EU
Marketed 3 Years – Sunset Clause
![Page 14: Regulatory affairs fin](https://reader033.fdocuments.net/reader033/viewer/2022050815/5456ad74af79592b438b6562/html5/thumbnails/14.jpg)
Evaluation by the European Agency
Authorised
EPAR European Public Assesment Report
EPARBriefSmPC; PIL; Label Authorised products
http://www.emea.europa.eu/ema/
![Page 15: Regulatory affairs fin](https://reader033.fdocuments.net/reader033/viewer/2022050815/5456ad74af79592b438b6562/html5/thumbnails/15.jpg)
1MAA - EU1MAA - EU
1 MAA / 1 MAA / differents differents countriescountries
1 MAA /Country1 MAA /Country National ProcedureNational Procedure
MRPMRP DCPDCP
CPCP
Conflict; disputeConflict; dispute
ReferralReferral
PROCEDURES / REFERRAL
![Page 17: Regulatory affairs fin](https://reader033.fdocuments.net/reader033/viewer/2022050815/5456ad74af79592b438b6562/html5/thumbnails/17.jpg)
![Page 18: Regulatory affairs fin](https://reader033.fdocuments.net/reader033/viewer/2022050815/5456ad74af79592b438b6562/html5/thumbnails/18.jpg)
www.pharmatalents.es
You can find us in Pharma Talents / LinkedIn &
Follow us inTwitter @talentspharma
![Page 19: Regulatory affairs fin](https://reader033.fdocuments.net/reader033/viewer/2022050815/5456ad74af79592b438b6562/html5/thumbnails/19.jpg)